Final answer:
The correct answer to which biologics can exacerbate inflammatory bowel disease or cause new-onset IBD is (D) All of the above. Infliximab, adalimumab, and vedolizumab are all used to treat IBD but in rare cases, they may worsen the disease or trigger new-onset of symptoms.
Step-by-step explanation:
Impact of Biologics on Inflammatory Bowel Disease (IBD)
Inflammatory bowel disease (IBD) is a group of disorders that involve chronic inflammation of the digestive tract. The main types are Crohn's disease, which can affect any part of the gastrointestinal (GI) tract, and ulcerative colitis, which is primarily localized to the colon and rectum. Treatments for IBD often involve biologics, which are a class of drugs made from living organisms or contain components of living organisms. Biologics are designed to target specific parts of the immune system that contribute to the inflammatory process in IBD.
The question regarding which biologics can exacerbate inflammatory bowel disease or cause new-onset IBD is interesting because biologics are generally used as treatments for IBD. The answer is (D) All of the above. Infliximab, adalimumab, and vedolizumab are all biologics used in the treatment of IBD.
However, each of these medications functions differently, and while they generally help to manage IBD, there are rare instances where they can worsen the disease or potentially trigger new onset of IBD-like symptoms, usually due to complex immune reactions. It's important to note that this is not the typical response and these medications are usually quite beneficial.